IRIS
SANTORO, Armando
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 37.535
AS - Asia 22.610
EU - Europa 6.908
SA - Sud America 4.468
AF - Africa 1.218
Continente sconosciuto - Info sul continente non disponibili 45
OC - Oceania 38
AN - Antartide 1
Totale 72.823
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 36.649
SG - Singapore 14.178
BR - Brasile 3.677
CN - Cina 3.256
VN - Vietnam 2.305
FI - Finlandia 1.406
IE - Irlanda 1.123
IT - Italia 946
NG - Nigeria 809
DE - Germania 732
HK - Hong Kong 690
FR - Francia 649
CA - Canada 562
GB - Regno Unito 457
IN - India 432
NL - Olanda 372
SE - Svezia 317
AR - Argentina 294
TR - Turchia 282
BD - Bangladesh 232
IQ - Iraq 194
RU - Federazione Russa 182
MX - Messico 166
IL - Israele 145
EC - Ecuador 138
ID - Indonesia 117
ZA - Sudafrica 115
JP - Giappone 112
PL - Polonia 104
BE - Belgio 98
UA - Ucraina 97
CO - Colombia 96
PK - Pakistan 86
ES - Italia 82
CL - Cile 78
MA - Marocco 78
UZ - Uzbekistan 66
VE - Venezuela 63
SA - Arabia Saudita 54
PY - Paraguay 53
PH - Filippine 46
MY - Malesia 41
JO - Giordania 40
EG - Egitto 36
TN - Tunisia 36
AE - Emirati Arabi Uniti 35
RO - Romania 35
IR - Iran 34
CZ - Repubblica Ceca 33
LT - Lituania 33
AT - Austria 32
AU - Australia 32
DZ - Algeria 32
KE - Kenya 32
KR - Corea 31
UY - Uruguay 30
NP - Nepal 29
JM - Giamaica 25
DO - Repubblica Dominicana 24
KZ - Kazakistan 24
CR - Costa Rica 23
OM - Oman 23
PE - Perù 23
AZ - Azerbaigian 22
CH - Svizzera 22
A2 - ???statistics.table.value.countryCode.A2??? 21
EU - Europa 21
BG - Bulgaria 20
ET - Etiopia 18
HU - Ungheria 18
TH - Thailandia 18
HN - Honduras 17
GR - Grecia 16
TT - Trinidad e Tobago 16
LB - Libano 15
PT - Portogallo 15
SN - Senegal 14
NO - Norvegia 13
TW - Taiwan 13
BY - Bielorussia 12
PA - Panama 12
AL - Albania 11
AM - Armenia 11
BO - Bolivia 11
KG - Kirghizistan 11
NI - Nicaragua 11
RS - Serbia 10
SI - Slovenia 10
SY - Repubblica araba siriana 10
BH - Bahrain 9
HR - Croazia 9
KW - Kuwait 9
PS - Palestinian Territory 9
CG - Congo 8
CI - Costa d'Avorio 8
DK - Danimarca 8
GT - Guatemala 8
LV - Lettonia 8
LY - Libia 8
MD - Moldavia 8
Totale 72.701
Salva come PNG Salva come JPEG
Città #
Singapore 6.528
Wilmington 5.541
Chandler 4.574
The Dalles 2.233
Ashburn 2.180
San Mateo 2.024
Dallas 1.785
Ann Arbor 1.546
Shanghai 1.468
Helsinki 1.397
San Jose 1.360
Dublin 1.115
Leawood 943
Princeton 912
Lawrence 911
Boardman 837
New York 824
Benin City 804
Ho Chi Minh City 784
Beijing 690
Hong Kong 639
Hanoi 556
Paris 515
Woodbridge 515
Fairfield 512
Los Angeles 375
Toronto 332
Amsterdam 328
Santa Clara 321
São Paulo 305
Milan 291
Seattle 239
London 227
Buffalo 207
Kocaeli 180
Columbus 172
San Diego 167
Council Bluffs 162
Rio de Janeiro 132
Phoenix 130
Norwalk 119
Da Nang 112
Haiphong 97
Orem 97
Belo Horizonte 93
Brussels 87
Warsaw 85
Tokyo 82
Falkenstein 79
Pune 78
Falls Church 74
Montreal 74
Chicago 69
Baghdad 67
Brooklyn 66
Chennai 65
Brasília 63
Curitiba 63
Tashkent 63
Charlotte 62
Redwood City 60
Porto Alegre 58
Munich 57
Naples 57
Johannesburg 56
Guayaquil 55
Mexico City 55
Moscow 54
Dhaka 50
Monmouth Junction 50
Campinas 48
Frankfurt am Main 46
Hải Dương 46
Manchester 46
San Francisco 45
Atlanta 44
Biên Hòa 43
Abbiategrasso 39
Houston 38
Mumbai 38
Salvador 38
Boston 37
Erbil 37
Redmond 37
Amman 36
Stockholm 36
Denver 35
Goiânia 35
Istanbul 34
Hillsboro 33
Quito 32
Thái Bình 32
Fortaleza 31
Guarulhos 31
Santiago 31
Assago 30
Rome 30
Des Moines 29
Pasadena 29
Asunción 28
Totale 48.002
Salva come PNG Salva come JPEG
Nome #
Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis 172
KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL) 166
Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer 164
An exploratory biomarker study in metastatic tumors from colorectal cancer patients treated with bevacizumab 157
18F-FDG PET and CT scan in the pre-operative evaluation of colorectal liver metastases treated with chemotherapy 157
18F-FDG pet does not improve contrast enhanced CT scan sensitivity in the evaluation of liver metastases after chemotherapy 153
A Case of Pulmonary Sarcoidosis during First-Line Targeted Therapy with Dabrafenib Plus Trametinib in BRAF V600E-Mutated Metastatic Melanoma 145
A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma 142
A reduced dose of fluconazole as primary antifungal prophylaxis is not associated with increased risk of invasive fungal infections after allogenic stem call transplantation from a HLA identical sibling 141
Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases 141
A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial 138
A PHASE 1 SAFETY STUDY OF ONCOFID-P-B ADMINISTERED FOR 12 CONSECUTIVE WEEKS IN BCG UNRESPONSIVE/INTOLERANT PATIENTS WITH BLADDER CARCINOMA IN SITU (CIS): PRELIMINARY RESULTS 138
Primary refractory and early-relapsed Hodgkin's lymphoma : strategies for therapeutic targeting based on the tumour microenvironment 137
Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases 137
A new human cell line, PDSS-26, from poorly differentiated synovial sarcoma, with unique chromosomal anomalies 136
Gene methylation in pleural mesothelioma : Correlations with clinico-pathological features and patient’s follow-up 135
Are three weeks hypofractionated radiation therapy (HFRT) comparable to six weeks for newly diagnosed glioblastoma patients? Results of a phase II study 134
BMS-986148, an anti-mesothelin antibody-drug conjugate (ADC), alone or in combination with nivolumab demonstrates clinical activity in patients with select advanced solid tumors 133
Role of consolidation RT to bulky lesions of advanced Hodgkin lymphoma: results of FIL HD0801 trial 133
A phase I clinical and pharmacokinetic study evaluating vinflumine in combination with epirubicin as first-line treatment in metastatic breast cancer 129
Assessment of prognostic factors in patients with metastatic epidural spinal cord compression (MESCC) from solid tumor after surgery plus radiotherapy: a single institution experience 129
Metastasis of hepatocellular carcinoma to the heart: A case report and review of the literature 128
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study 128
A Phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small cell lung cancer. 128
Carbon-11-methionine PET-CT as an imaging biomarker in brain gliomas eligible for surgery 127
A circulating miRNA signature to implement diagnostic imaging analysis in young early-stage breast cancer patients 127
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma 126
A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer 125
Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study 124
Cerebrospinal fluid tumor DNA for liquid biopsy in glioma patients’ management: close to clinic 123
Addition of temozolomide to radiotherapy for treatment of newly diagnosed anaplastic gliomas 123
Hypofractionation with simultaneous boost in breast cancer patients receiving adjuvant chemotherapy: A prospective evaluation of a case series and review of the literature 122
Administration of temozolomide during and after radiotherapy for newly diagnosed high-grade gliomas excluding glioblastoma multiforme 122
Initial chemotherapy for primary resectable large-cell lymphoma of the stomach 121
A first-in-human phase 1/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignancies 120
Tivantinib for hepatocellular carcinoma 120
A. Micrometastasis in sentinel (SLN) and non sentinel lymph nodes of breast cancer: an update including clinico-pathologic impact and survaival 120
High incidence of hypocalcemia and serum creatinine increase in patients with bone metastases treated with zoledronic acid 119
Biological characteristics and long-term outcomes in node-negative breast cancer 119
VINORELBINE (V) IN PEMETREXED-PRETREATED PATIENTS (PTS) WITH MALIGNANT PLEURAL MESOTHELIOMA (MPM) 119
A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients with Advanced Hepatocellular Carcinoma 118
An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers 117
Tivantinib for Second-line Treatment of Advanced MET-High Hepatocellular Carcinoma: A Phase 3, Randomized, Placebo-Controlled Study (METIV-HCC) 116
Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up 113
A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer 112
Alternating drug combinations in the treatment of advanced Hodgkin's disease. 112
Biomarkers in Hepatocellular Carcinoma-Letter 110
Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy 110
Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC) 109
COMBINED-MODALITY TREATMENT FOR PRIMARY GASTROINTESTINAL NON-HODGKINS-LYMPHOMA - THE MILAN CANCER INSTITUTE EXPERIENCE 109
A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis 109
Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma 109
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma 109
Outcome appraisal of patients with limited brain metastases (BMs) from non small cell lung cancer (NSCLC) treated with different local therapeutic strategies: a single institute evaluation. 108
COVID-19 and liver cancer clinical trials: not everything is lost 108
. The level of HER2/neu amplification may have a correlation with some relevant histopathologcal features of early stage breast cancer 108
Clinical Effects of Driver Somatic mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With allogeneic Hematopoietic Stem-Cell Transplantation 107
Clinical relevance of clonal hematopoiesis in persons aged ≥80 years 107
A Comparative Study of Methyl-BEAMing and Droplet Digital PCR for MGMT Gene Promoter Hypermethylation Detection 106
Cyclic delivery of MOPP and ABVD combinations in Stage IV Hodgkin's disease: rationale, background studies, and recent results. 106
Pharmacological inactivation of DNA repair to improve response to immunotherapy: The Arethusa trial in metastatic colorectal cancer 106
Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with solid tumors 106
Treatment of malignant pleural mesothelioma: current status and future directions 106
Allogeneic stem cell transplantation in poor prognosis peripheral T-cell lymphoma: the impact of different donor type on outcome 106
Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma 105
Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer 105
Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications 105
Utility of 18F-FDG PET and contrast-enhanced CT scan in the assessment of residual liver metastasis from colorectal cancer following adjuvant chemotherapy 105
Superiority of CHOI vs RECIST criteria in evaluating outcome of advanced soft tissue sarcoma (STS) patients treated with sorafenib 105
Anatomic location of breast cancer micrometastasis in sentinel lymph node predicts axillary status 104
Advanced colorectal liver metastases and surgery after preoperative chemotherapy : is response-based selection enough? 103
DEXAMETHASONE, GRANISETRON, OR BOTH FOR THE PREVENTION OF NAUSEA AND VOMITING DURING CHEMOTHERAPY FOR CANCER 103
Survival outcome and prognostic factors after pulmonary metastasectomy in sarcoma patients 102
Advances in the biology of malignant pleural mesothelioma 102
A monocentric retrospective analysis of TILs and AR as hints for prognosis definition in TNBC 102
Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Gemcitabine/Cisplatin Alone or With Sorafenib for the First-Line Treatment of Advanced, Nonsquamous Non-Small-Cell Lung Cancer. 101
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer 101
Adjuvant volumetric modulated arc therapy compared to 3D conformal radiation therapy for newly diagnosed soft tissue sarcoma of the extremities: outcome and toxicity evaluation 101
Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. 101
Checkpoint inhibitors as treatment for malignant gliomas: "A long way to the top" 101
Hypofractionated radiation therapy (HFRT) versus conventional fractionated radiation therapy (CRT) for newly diagnosed glioblastoma patients. A propensity score matched analysis. 100
Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study 100
A Comprehensive Genetic Study of Classical Hodgkin Lymphoma Using Circulating Tumor DNA 99
High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant 99
A. Micrometastasis in sentinel (SLN) and non sentinel lymph nodes of breast cancer: an update including clinico-pathologic impact and survaival 99
A phase Ib/II trial of capmatinib plus spartalizumab vs. spartalizumab alone in patients with pretreated hepatocellular carcinoma 98
Cardioprotection with nebivolol in patients undergoing anthracyclines: a randomized placebo-controlled trial 98
Short schedule of cisplatin and vinorelbine: A dose-finding study in non-small-cell lung cancer 98
PHASE II STUDY OF THE COMBINATION OF BEVACIZUMAB PLUS PEMETREXED AND CARBOPLATIN AS FIRST-LINE THERAPY IN PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA (MPM) 98
Imatinib mesylate in desmoplastic small round cell tumour 98
Activity of single agent vinorelbine in pretreated non-Hodgkin's lymphoma 97
Dual PI3K/ERK inhibition induces necroptotic cell death of Hodgkin Lymphoma cells through IER3 downregulation 97
Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach 96
Long-Term Follow-up Results of the DANTE Trial, a Randomized Study of Lung Cancer Screening with Spiral Computed Tomography 96
Neutrophil to Lymphocyte Ratio (NLR) as predictive factor in patients with metastatic soft tissue sarcoma (STS) treated with trabectedin (T). 96
Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: Can it be safely associated with fluorouracil-based chemotherapy? 95
Pilot study with adriamycin and ifosfamide in small cell lung cancer. 95
Adjuvant Treatment of High-Risk, Radically Resected Gastric Cancer Patients With 5-Fluorouracil, Leucovorin, Cisplatin, and Epidoxorubicin in a Randomized Controlled Trial. 95
AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patients 95
Checkpoint Inhibitors as High-Grade Gliomas Treatment: State of the Art and Future Perspectives 95
Totale 11.575
Salva come PNG Salva come JPEG
Categoria #
all - tutte 505.846
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 505.846
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.032 0 0 0 0 0 0 0 0 0 0 0 1.032
2021/20225.036 371 72 123 1.100 86 83 202 732 426 556 1.050 235
2022/202312.810 2.013 413 1.232 1.406 1.154 1.075 32 1.083 2.224 1.120 906 152
2023/20246.764 616 732 1.517 242 195 721 323 368 87 140 696 1.127
2024/202510.261 245 192 54 176 234 1.187 534 1.207 1.458 2.604 1.158 1.212
2025/202628.339 4.175 1.970 1.856 2.948 755 1.187 8.085 1.668 1.676 1.707 1.130 1.182
Totale 73.568